[go: up one dir, main page]

MX2024006091A - Metodo para el tratamiento de una enfermedad de esclerodermia. - Google Patents

Metodo para el tratamiento de una enfermedad de esclerodermia.

Info

Publication number
MX2024006091A
MX2024006091A MX2024006091A MX2024006091A MX2024006091A MX 2024006091 A MX2024006091 A MX 2024006091A MX 2024006091 A MX2024006091 A MX 2024006091A MX 2024006091 A MX2024006091 A MX 2024006091A MX 2024006091 A MX2024006091 A MX 2024006091A
Authority
MX
Mexico
Prior art keywords
treatment
scleroderma
scleroderma disease
disease
localized
Prior art date
Application number
MX2024006091A
Other languages
English (en)
Inventor
Timothy Scott Johnson
John Atkinson
Jorg Hans Wilhelm Distler
David John Abraham
Original Assignee
UCB Biopharma SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by UCB Biopharma SRL filed Critical UCB Biopharma SRL
Publication of MX2024006091A publication Critical patent/MX2024006091A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo antitransglutaminasa de tipo 2 (TG2) para su uso en el tratamiento de una enfermedad de esclerodermia, tal como la esclerodermia localizada o sistémica.
MX2024006091A 2021-11-18 2022-11-17 Metodo para el tratamiento de una enfermedad de esclerodermia. MX2024006091A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB2116665.7A GB202116665D0 (en) 2021-11-18 2021-11-18 Method for the treatment of a scleroderma disease
PCT/EP2022/082293 WO2023089037A1 (en) 2021-11-18 2022-11-17 Method for the treatment of a scleroderma disease

Publications (1)

Publication Number Publication Date
MX2024006091A true MX2024006091A (es) 2024-05-30

Family

ID=79163875

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2024006091A MX2024006091A (es) 2021-11-18 2022-11-17 Metodo para el tratamiento de una enfermedad de esclerodermia.

Country Status (13)

Country Link
US (1) US20250026856A1 (es)
EP (1) EP4433516A1 (es)
JP (1) JP2024540595A (es)
CN (1) CN118317977A (es)
AR (1) AR127713A1 (es)
AU (1) AU2022392415A1 (es)
CA (1) CA3238337A1 (es)
CL (1) CL2024001478A1 (es)
CO (1) CO2024006327A2 (es)
GB (1) GB202116665D0 (es)
MX (1) MX2024006091A (es)
TW (1) TW202334241A (es)
WO (1) WO2023089037A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025153465A1 (en) 2024-01-15 2025-07-24 UCB Biopharma SRL Method for the treatment of fibrotic-related disorder associated to ibd

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006100679A2 (en) 2005-03-22 2006-09-28 Quark Pharmaceuticals, Inc. Recombinant antibodies against human type ii transglutaminase and uses thereof
GB2490655A (en) 2011-04-28 2012-11-14 Univ Aston Modulators of tissue transglutaminase
GB201209096D0 (en) 2012-05-24 2012-07-04 Medical Res Council Technology Compounds
GB201411320D0 (en) 2014-06-25 2014-08-06 Ucb Biopharma Sprl Antibody construct

Also Published As

Publication number Publication date
CN118317977A (zh) 2024-07-09
WO2023089037A1 (en) 2023-05-25
EP4433516A1 (en) 2024-09-25
GB202116665D0 (en) 2022-01-05
US20250026856A1 (en) 2025-01-23
AU2022392415A1 (en) 2024-06-27
CA3238337A1 (en) 2023-05-25
CO2024006327A2 (es) 2024-07-18
CL2024001478A1 (es) 2024-09-06
JP2024540595A (ja) 2024-10-31
AR127713A1 (es) 2024-02-21
TW202334241A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
MX2022002075A (es) Usos terapeuticos de anticuerpos anti-variable delta 1 de tcr.
CO2020009625A2 (es) Inhibidor de fap
CY1113190T1 (el) Μεθοδος αγωγης της αιμολυτικης νοσου
MX2019007586A (es) Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares.
PE20161390A1 (es) Anticuerpos multiespecificos
MX2021014853A (es) Variante de proteina de exportacion de l-treonina y procedimiento para la produccion de l-treonina mediante el uso de la misma.
DOP2021000044A (es) Moduladores de la expresión de pnpla3
MX2022011972A (es) Composiciones que comprenden anticuerpos contra il6r para el tratamiento de la uveitis y el edema macular, y metodos de uso de las mismas.
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
EA201891664A1 (ru) Составы/композиции, содержащие ингибитор btk
CL2021001922A1 (es) Procedimientos para tratamiento de enfermedades con inhibidores de magl.
BR112022004861A2 (pt) Alvelestat para uso no tratamento de rejeição de transplante, síndrome de bronquiolite obliterante e doença de transplante versus hospedeiro
MX2020008125A (es) Composiciones que comprenden berberina.
EA202191058A1 (ru) Антитела против муцина-16 и способы их применения
UY38352A (es) Inhibidores de integrina alfavbeta6
MX2024006091A (es) Metodo para el tratamiento de una enfermedad de esclerodermia.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
CL2021001246A1 (es) Moduladores de expresión irf5.
CO2017012397A2 (es) Fragmento de anticuerpo fab anti-ngf humano
MX2020011377A (es) Metodos y composiciones para el tratamiento de urticaria cronica.
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
MX2022004422A (es) Metodo para el tratamiento del cabello.
MX2021012848A (es) Mirikizumab para su uso en un metodo de tratamiento de la enfermedad de crohn.
CO2020003134A2 (es) Moduladores de la expresión de enac
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб